Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Acceleron and Celgene land another big blow with their TGF blocker
Company: Acceleron (XLRN) and Celgene (CELG)
Therapy: Lustpatercept
Disease: Beta-thalassemia
News: Following on recent news that lustpatercept improved survival in patients with lower-risk myelodysplastic syndrome, XLRN and CELG have announced that the BELIEVE study also met its primary study endpoint of erythroid response, defined as a reduction of transfusion